TriSalus Life Sciences, Inc. (TLSI) Operating Margin
- Operating margin · 12 months: Value -67.68%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -67.68% | Operating income / revenue. Period ending 2026-06-30. $-30.51M ÷ $45.08M × 100 ≈ -67.68% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -30.51M USD | Operating Income (Loss) |
| Revenue | 45.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.41M USD | Cost of Goods and Services Sold |
| Research and development | 14.63M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-30.51M | $45.08M | $6.41M | $14.63M | (m) | -67.68% |
| 2026-03-31 | $-28.03M | $44.88M | $6.70M | $15.16M | (m) | -62.45% |
| 2025-12-31 | $-26.95M | $45.15M | $6.96M | $14.96M | (m) | -59.68% |
| 2025-09-30 | $-31.25M | $40.21M | $6.42M | $15.35M | (m) | -77.74% |
| 2025-06-30 | $-30.98M | $35.99M | $5.52M | $14.40M | (m) | -86.08% |
| 2025-03-31 | $-31.82M | $32.14M | $4.63M | $15.14M | (m) | -99.01% |
| 2024-12-31 | $-36.16M | $29.43M | $4.10M | $17.69M | (m) | -122.88% |
| 2024-09-30 | $-42.51M | $26.89M | $3.47M | $22.17M | (m) | -158.08% |
| 2024-06-30 | $-52.45M | $24.74M | $3.05M | $27.53M | (m) | -212.06% |
| 2024-03-31 | $-55.71M | $21.98M | $2.91M | $29.73M | (m) | -253.43% |
| 2023-12-31 | $-54.15M | $18.51M | $2.60M | $29.51M | (m) | -292.53% |
| 2023-09-30 | $-18.11M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-4.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-2.92M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-2.75M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-2.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-2.91M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-3.40M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-3.04M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |